Zacks: Analysts Expect GALAPAGOS NV/S (GLPG) Will Post Earnings of -$1.39 Per Share
Wall Street brokerages expect GALAPAGOS NV/S (NASDAQ:GLPG) to post earnings of ($1.39) per share for the current quarter, Zacks reports. Four analysts have issued estimates for GALAPAGOS NV/S’s earnings. The highest EPS estimate is ($1.10) and the lowest is ($1.84). GALAPAGOS NV/S reported earnings per share of ($0.90) in the same quarter last year, which indicates a negative year over year growth rate of 54.4%. The business is scheduled to announce its next earnings results on Wednesday, April 24th.
On average, analysts expect that GALAPAGOS NV/S will report full-year earnings of ($4.96) per share for the current fiscal year, with EPS estimates ranging from ($7.32) to ($4.15). For the next financial year, analysts forecast that the company will post earnings of ($5.26) per share, with EPS estimates ranging from ($7.28) to ($3.85). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for GALAPAGOS NV/S.
A number of equities analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of GALAPAGOS NV/S in a report on Thursday, March 28th. They issued a “buy” rating and a $136.00 target price on the stock. BidaskClub cut shares of GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. Cantor Fitzgerald set a $130.00 target price on shares of GALAPAGOS NV/S and gave the company a “buy” rating in a report on Tuesday, March 26th. ValuEngine raised shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 4th. Finally, Leerink Swann started coverage on shares of GALAPAGOS NV/S in a report on Friday, February 22nd. They issued an “outperform” rating and a $140.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. GALAPAGOS NV/S presently has a consensus rating of “Buy” and an average target price of $125.83.
Shares of GALAPAGOS NV/S stock traded up $0.69 during trading on Tuesday, reaching $115.00. The company’s stock had a trading volume of 136,966 shares, compared to its average volume of 201,716. The stock has a market capitalization of $5.86 billion, a price-to-earnings ratio of -43.56 and a beta of 1.68. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $125.48.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Recommended Story: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.